Eli Lilly, the makers of tirzepatide—which they sell as Mounjaro for diabetes and Zepbound for weight loss— announced recently that in its longest study yet on tirzepatide, the drug reduced the risk of people with prediabetes moving on to develop diabetes by 94% compared to those taking a placebo.

The weight-loss drug liraglutide (Saxenda) helped obese children lower their BMI and reach a healthier weight, researchers report.

Novo Nordisk's liraglutide has been approved for children who are at least 12 years old. However, the drug is now being tested on children as young as six years old.

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.

As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and GLP-1 (weight-loss) drugs,